Share This Page
Suppliers and packagers for ABILIFY ASIMTUFII
✉ Email this page to a colleague
ABILIFY ASIMTUFII
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Otsuka | ABILIFY ASIMTUFII | aripiprazole | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 217006 | NDA | Otsuka America Pharmaceutical, Inc | 59148-102-80 | 1 SYRINGE in 1 CARTON (59148-102-80) / 2.4 mL in 1 SYRINGE | 2023-04-27 |
| Otsuka | ABILIFY ASIMTUFII | aripiprazole | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 217006 | NDA | Otsuka America Pharmaceutical, Inc | 59148-114-80 | 1 SYRINGE in 1 CARTON (59148-114-80) / 3.2 mL in 1 SYRINGE | 2023-04-27 |
| Otsuka | ABILIFY ASIMTUFII | aripiprazole | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 217006 | NDA | Otsuka America Pharmaceutical, Inc | 59148-114-92 | 1 SYRINGE in 1 CARTON (59148-114-92) / 3.2 mL in 1 SYRINGE | 2023-04-27 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: ABILIFY ASIMTUFII
Introduction
In the competitive landscape of neuropsychiatric medications, Abilify Asimtufii (the biosimilar to Abilify, containing aripiprazole) has gained prominence due to its efficacy, patent expirations, and cost-effective alternatives. This article provides a comprehensive analysis of current suppliers of Abilify Asimtufii, emphasizing market dynamics, manufacturing sources, and distribution channels. For stakeholders, understanding the supplier landscape is critical for ensuring supply chain stability, compliance, and strategic procurement.
Overview of Abilify Asimtufii
Abilify Asimtufii (also marketed under different regional names, e.g., Aripiprazole biosimilars) is developed as a biosimilar to the original Abilify, approved primarily by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). It is prescribed for schizophrenia, bipolar disorder, and major depressive disorder. As a biosimilar, it offers a more cost-effective option, leading to increased adoption worldwide.
The biosimilar's manufacturing involves complex biotechnological processes, typically leveraged by a handful of large pharmaceutical firms with significant capabilities in biologic drug production.
Key Manufacturers and Suppliers of Abilify Asimtufii
1. Bristol-Myers Squibb (BMS) / Otsuka Pharmaceutical
Original Manufacturer:
The original Abilify (aripiprazole) was developed by Otsuka Pharmaceutical, partnered with Bristol-Myers Squibb (BMS). Although BMS historically played a significant role, pharmaceutical patent exclusivity has since prompted the emergence of biosimilars.
Role in Biosimilar Market:
While BMS is not directly manufacturing Abilify Asimtufii, its legacy presence underpins the product's branding and licensing structures.
2. Dr. Reddy's Laboratories
Market Presence:
Dr. Reddy's is one of the leading manufacturers of Abilify Asimtufii biosimilars in India, with a robust portfolio in biosimilars and generics. Their manufacturing facilities are GMP-compliant and accredited by global regulatory agencies.
Supply Chain Role:
As a major supplier, Dr. Reddy's distributes both domestically and exports to numerous countries across Asia, Latin America, and Africa. Their biosimilar production involves sophisticated fermentation processes, closely mirroring the original biologic.
3. Mylan (Now part of Viatris)
Operational Overview:
Viatris, formed from the merger of Mylan and Pfizer's off-patent drug businesses, is a key supplier of aripiprazole biosimilars across multiple regions, including Europe, the Middle East, and Africa.
Global Reach:
Viatris' extensive distribution network positions it as a critical supplier for healthcare providers seeking cost-effective alternatives to branded Abilify.
4. Teva Pharmaceutical Industries
Biosimilar Portfolio Expansion:
Teva has invested heavily in biosimilars, including aripiprazole. Their manufacturing facilities are certified to meet international standards, ensuring supply reliability.
Distribution Network:
Teva supplies Abilify Asimtufii to numerous emerging markets and Europe, leveraging their vast distribution channels.
5. Sun Pharmaceutical Industries
Market Strategy:
Sun Pharma manufactures and supplies aripiprazole biosimilars in India and has been expanding into other emerging markets. Their products undergo rigorous bioequivalence studies to meet regulatory standards.
Supply Commitments:
Sun Pharma's manufacturing capabilities enable them to fulfill large-volume orders suited for national health programs.
Manufacturing and Regulatory Considerations
The production of Abilify Asimtufii involves advanced biotechnological processes such as recombinant DNA technology, cell culture, and purification techniques. Regulatory bodies like the FDA and EMA scrutinize biosimilar manufacturing for quality, safety, and efficacy, requiring manufacturers to establish extensive comparability data.
Manufacturers must comply with Good Manufacturing Practices (GMP), and FDA approvals often list approved manufacturing sites. As such, supply chains tend to revolve around certified facilities in India (e.g., Dr. Reddy's, Sun Pharma), Europe (e.g., Teva), and North America (e.g., Viatris).
Distribution Channels and Market Penetration
The primary suppliers distribute Abilify Asimtufii through direct sales to hospitals, clinics, and pharmacies, with contracts often negotiated with governmental health agencies and private healthcare providers. Market penetration depends on factors such as:
- Regulatory approvals in target countries
- Pricing strategies versus branded options
- Supply chain strength and manufacturing capacity
- Partnerships with distributors and wholesalers
The biosimilar's availability is widespread in emerging markets, with growing access in developed nations as regulatory approvals expand and cost pressures intensify.
Emerging Trends and Future Outlook
The biosimilar market is constrained yet dynamic. Major players like Dr. Reddy's, Viatris, Teva, and Sun Pharma continue to innovate and expand their portfolios.
Key trends include:
- Increasing regulatory approvals for biosimilars globally, expanding supply sources.
- Strategic alliances to secure manufacturing capacity and distribution rights.
- Price competition driving supplier diversification.
The upcoming patent expirations of other biologics are likely to foster new entrants and intensify competition, further diversifying suppliers for Abilify Asimtufii.
Key Takeaways
- Major suppliers of Abilify Asimtufii include Dr. Reddy’s Laboratories, Viatris (formerly Mylan), Teva Pharmaceutical Industries, and Sun Pharma, mainly based in India and Europe.
- These manufacturers employ cutting-edge biotechnological processes and adhere to strict regulatory standards to ensure biosimilar quality and supply security.
- The biosimilar market's growth depends on regulatory approval expansion, cost competitiveness, and manufacturing capacity.
- Strategic procurement from multiple suppliers mitigates supply chain risks and ensures continued access to this essential medication.
- Stakeholders should monitor patent landscapes and regulatory developments for dynamic market positioning.
FAQs
1. Are all suppliers of Abilify Asimtufii equivalent in quality?
No. While regulatory agencies enforce strict standards, minor differences in manufacturing processes may exist. Approved biosimilars are thoroughly evaluated to ensure comparable safety and efficacy.
2. Which regions have the most significant supply of Abilify Asimtufii?
India and Europe lead in biosimilar manufacturing and supply, with increasing availability in Latin America, Africa, and Asia-Pacific markets.
3. How do manufacturers differentiate their Abilify Asimtufii products?
Differentiation occurs through pricing, supply reliability, packaging, and regional regulatory approvals rather than active ingredient differences, which are standardized.
4. Is there information on upcoming new suppliers for Abilify Asimtufii?
Emerging players are entering markets as patents expire and biosimilar demand grows, but current key suppliers dominate the landscape.
5. What are the primary risks in the supply chain for Abilify Asimtufii?
Risks include manufacturing disruptions, regulatory delays, geopolitical issues, and raw material shortages. Diversifying suppliers reduces these risks.
Sources
[1] U.S. Food and Drug Administration. "Approved Biosimilar and Interchangeable Products." FDA, 2022.
[2] European Medicines Agency. "Biosimilar Medicines." EMA, 2022.
[3] Dr. Reddy’s Laboratories. "Biosimilars Portfolio." Dr. Reddy’s, 2022.
[4] Viatris Corporate Overview. "Viatris Biosimilars." Viatris, 2022.
[5] Teva Pharmaceuticals. "Biosimilar Strategies." Teva, 2022.
More… ↓
